IPO Trending
MANKINDEQ / NSE, BSEListed

Mankind Pharma Limited

Incorporated in 1991, Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products across a wide range of acute and chronic therapeutic areas in India, including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins/minerals/nutrients, and respiratory. The company offers over 36 brands such as Manforce, Moxikind-CV, Amlokind-AT, Prega News, and Gudcef, supported by one of the largest distribution networks of medical representatives in India, with over 80% of doctors prescribing its formulations. Ranked 4th in domestic sales in FY2022, Mankind Pharma has received numerous awards, including The Best of Bharat Awards 2022, National Awards for Manufacturing Competitiveness Silver Medal 2021, and recognition for Best Design in Healthcare and performance management excellence.

₹1,026 - ₹1,08015.32x sub
Listed Price1300.00
Listing Gain+20.37%
FinancialsBalance sheet and operational figures in Crores
Metric Breakdown

Revenue

Latest (Mar 2020)5975.65 Cr
Growth-11.8%
Revenue Trend (₹ in Crores)
0.03.1k6.1k9.2kDec 2022Mar 2022Dec 2021Mar 2021Mar 2020
PeriodRev (Cr)PAT (Cr)AssetsDebt
Mar 20205,975.651,056.155,073.29126.92
Mar 20216,385.381,293.036,372.63234.53
Dec 20216,218.291,260.248,043.88268.70
Mar 20227,977.581,452.969,147.74868.03
Dec 20226,777.821,015.989,273.75167.93
Key Performance Indicators (KPIs)
PeriodEPSROEROCEP/E (Pre)P/E (Post)
Values33.2027.60%26.10%32.50